This clinical trial is focused on studying a condition known as non-transfusion-dependent alpha- or beta-thalassemia. Thalassemia is a blood disorder that affects the body’s ability to produce hemoglobin, which is essential for carrying oxygen in the blood. People with this condition do not require regular blood transfusions. The study is testing a treatment called Mitapivat, which is taken in tablet form. Mitapivat is being compared to a placebo to see how effective it is in treating anemia, a condition where there is a lack of healthy red blood cells, in individuals with this type of thalassemia.

The purpose of the study is to evaluate the effectiveness and safety of Mitapivat in improving anemia in patients with non-transfusion-dependent thalassemia. Participants in the study will be randomly assigned to receive either Mitapivat or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased. The study will take place over several weeks, with regular check-ups to monitor the participants’ health and response to the treatment.

Throughout the study, the main goal is to observe if there is an increase in hemoglobin levels, which would indicate an improvement in anemia. Participants will be closely monitored to ensure their safety and to gather data on how well Mitapivat works compared to the placebo. This research aims to provide valuable information that could lead to better treatment options for individuals with non-transfusion-dependent thalassemia.